Biohaven Ltd. (BHVN)
NYSE:BHVN
Want to see BHVN full AI Analyst Report?
BHVN Stock Chart & Stats
$10.98
-$0.59(-1.49%)
At close: 4:00 PM EST
$10.98
-$0.59(-1.49%)
Day’s Range― - ―
52-Week Range$7.48 - $24.06
Previous CloseN/A
Volume146.24K
Average Volume (3M)2.32M
Market Cap
$1.49B
Enterprise Value$1.09B
Total Cash (Recent Filing)$319.14M
Total Debt (Recent Filing)$278.86M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
May 08, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.21
Shares Outstanding150,420,580
10 Day Avg. Volume1,742,120
30 Day Avg. Volume2,317,298
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)23.33
Price to Sales (P/S)0.00
P/FCF Ratio-1.99
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-530.19
Enterprise Value/Ebitda-1.47
Forecast
1Y Price Target
$21.44Price Target Upside95.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Lead Epilepsy Asset PotentialAnalyst views the lead epilepsy candidate as undervalued given the large epilepsy market and the potential for strong sales if pivotal trials confirm efficacy.
Pipeline Diversification And High-value AssetsA streamlined pipeline focused on four core assets, including protein degraders and a kidney disease candidate, offers multiple high-impact opportunities that could materially increase company value if late-stage programs succeed.
Safety And Tolerability AdvantageEarly signals and the Kv7 mechanism suggest the epilepsy drug could match seizure reduction of a class rival while producing fewer central nervous system side effects, which may support prescriber uptake based on tolerability.
Bears Say
Competitive Positioning And TimingOpakalim is positioned behind a competitor with strong confirmatory trial results, and being second to market combined with physician treatment inertia could limit initial commercial share despite tolerability benefits.
Financing And Execution RiskReduced cash burn still leaves financial risk that depends on additional clinical successes, and a financing overhang could keep shares range bound without unexpectedly positive trial outcomes.
Regulatory UncertaintyA regulatory setback for another program and an ongoing appeals process increase development and regulatory risk, which could delay approvals and add uncertainty to value realization.
Biohaven Ltd. News
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $7.48 and its highest was $24.06 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Biohaven Ltd.’s market cap is $1.49B.
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is May 08, 2026 which is in 12 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on Mar 02, 2026. The company reported -$1.21 earnings per share for the quarter, missing the consensus estimate of -$1.188 by -$0.022.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -0.83.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 150,420,580 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$1.21 in its last earnings report, missing expectations of -$1.188. Following the earnings report the stock price went down -9.653%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Currently, no hedge funds are holding shares in BHVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biohaven Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.44 (95.30% Upside)
$21.44 (95.30% Upside)
Blogger Sentiment
Bearish
BHVN Sentiment 67%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.09%
12-Months-Change
Fundamentals
Return on Equity
-688.89%
Trailing 12-Months
Asset Growth
-26.61%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
BHVN Stock 12 Month Forecast
Average Price Target
$21.44
▲(95.30% Upside)
Technical Analysis
Ownership Overview
10.78% Insiders
8.62% Mutual Funds
0.08% Other Institutional Investors
70.62% Public Companies and
Individual Investors